Tandy Agostini, MD
Gastroenterology · Ithaca, NYNPI 1134642135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 31.6% of the total. That places this record below the midpoint for gastroenterology clinicians in NY, where the typical reported total is $1,827.
Across 9 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$88
- Braintree Laboratories, Inc.$42
- Takeda Pharmaceuticals U.S.A., Inc.$41
- Johnson & Johnson$29
- Ferring Pharmaceuticals Inc.$28
- Gilead$21
- plus $30 from 2 others
What the payments were for
- Food & beverage$280100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $88 |
| Braintree Laboratories, Inc. | 1 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Johnson & Johnson | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Gilead | 1 | $21 |
| AstraZeneca | 1 | $15 |
| Pentax Of America, Inc. | 1 | $15 |
How this compares
$280 in reported general payments places this provider in the 20th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 25 | $20,189 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 24 | $1,282 |
| Omeprazole | 79 | $1,141 |
| Pantoprazole Sodium | 18 | $254 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $248 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Ithaca
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.